Icosavax competitors

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

Christopher J. Schaber, PhD has over 30 years experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been Soligenix's President and Chief Executive Officer and a director since August 2006. He also served on the board of directors for the Alliance for BioSecurity and for the Biotechnology Council of NJ (BioNJ), where he is currently Chair. He has been a member of the corporate councils for both the National Organization for Rare Disorders (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT). Prior to joining the company, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA from Western Maryland College, his MS in Pharmaceutics from Temple University School of Pharmacy and his PhD in Pharmaceutical Sciences from the Union Graduate School. During his career, Dr. Schaber has played a significant role in raising in excess of $300 million through both public offerings and private placements, as well as over $80 million through the achievement of government grant and contract awards.

Martin Moore is a Founder and CEO at Meissa Vaccines and is based in San Carlos, California. He has worked as Associate Professor at Emory University School of Medicine and Founder and CSO at Meissa Vaccines. Marty studied at Vanderbilt University School of Medicine between 2004 and 2008, University of Georgia between 1998 and 2003, and University of Georgia between 1990 and 1995.

Innovative Business Builder | Transformation Leader | Investor | Strategic Advisor Long track record of value creation and innovation as an executive, strategic investor, and advisor focused on transformation, growth and capital efficiency. Deep experience in biopharma, but also in a variety of other industries, including consumer goods, technology, and financials. Leveraging a diverse background to spur creative thinking by harnessing cross-pollination across unrelated areas and disciplines. Global experience across North America, Europe, and Asia. Featured in the Wall Street Journal for starting a ground-breaking charity that reached 10 million people in 106 countries. Instrument-rated pilot, crossed the Atlantic twice flying a twin propeller Cessna.